QualityStocks.net News – China Biopharmaceuticals Holding Inc. (CHBP.OB) Posts 78 Percent Increase in Q1 Revenue

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight China Biopharmaceuticals Holding Inc. (OTCBB: CHBP). The company is a vertically integrated pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of small and large molecule pharmaceutical products, including medicines, vaccines, and active pharmaceutical ingredients for various categories of diseases. CHBP is a U.S.-listed public company with operating subsidiaries and senior management based in China.

In the Company’s recent news,

China Biopharmaceuticals Holding Inc. (OTCBB: CHBP) announced its first quarter results for the period ended March 31, 2008. China Biopharmaceuticals posted first quarter revenue at $10.9 million, up 78 percent from $6.1 million last year. The company attributes the increase to the rise in price and sales of its raw material drugs at its main manufacturing plant, Erye; the revamped medical insurance system in China, promoting Erye’s drugs; and the increased price of freeze-dried drugs.

Net income was $492,076 for the first quarter of 2008, up $669,869 from the loss of $177,793 for the same period last year. Madame Zhang Jian, chairwoman and CFO of China Biopharmaceuticals, said the company’s marketing strategy and its high-margin product line helped boost first quarter revenue. The company intends to continue its active pursuit of growth and expansion opportunities, which it believes can be achieved with internal growth and acquisitions.

“We are extremely pleased to report a healthy quarterly profit and strong cashflow on record revenues,” Jian stated in the press release. “We have made huge strides in overcoming the Enshi problems and getting back to focusing on building a successful business. Going forward we intend to build upon the momentum established during the first quarter of 2008 to have a very strong performance for the rest of the year.”

“We anticipate that our internally generated financial resources are sufficient to provide for our organic growth. These are the keys to creating a very valuable enterprise for our shareholders. We are looking forward to new opportunities of growth and opportunities in the pharmaceutical manufacturing and stemcell fields,” Chris Mao, CEO of China Biopharmaceuticals stated.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.